IGM Biosciences, Inc. Stock price

Equities

IGMS

US4495851085

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
10.44 USD -1.88% Intraday chart for IGM Biosciences, Inc. -0.10% +25.63%
Sales 2024 * 3.04M Sales 2025 * 13.78M Capitalization 625M
Net income 2024 * -199M Net income 2025 * -222M EV / Sales 2024 * 151 x
Net cash position 2024 * 168M Net cash position 2025 * 170M EV / Sales 2025 * 33.1 x
P/E ratio 2024 *
-3.26 x
P/E ratio 2025 *
-3.74 x
Employees 224
Yield 2024 *
-
Yield 2025 *
-
Free-Float 36.48%
More Fundamentals * Assessed data
Dynamic Chart
HC Wainwright Adjusts IGM Biosciences Price Target to $12 From $7, Maintains Neutral Rating MT
Earnings Flash (IGMS) IGM BIOSCIENCES Reports Q4 Revenue $651,000 MT
IGM Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
IGM Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
RBC Upgrades IGM Biosciences to Outperform From Sector Perform, Boosts Price Target to $21 From $9; Speculative Risk Kept MT
Transcript : IGM Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 11:15 AM
North American Morning Briefing : Stock Futures -2- DJ
BofA Securities Downgrades IGM Biosciences to Neutral From Buy, Adjusts Price Target to $8 From $20 MT
IGM Biosciences, Inc.(NasdaqGS:IGMS) dropped from NASDAQ Biotechnology Index CI
North American Morning Briefing : Futures Pause -2- DJ
HC Wainwright Downgrades IGM Biosciences to Neutral From Buy, Cuts Price Target to $7 From $11 MT
Wedbush Raises IGM Biosciences' PT to $20 From $16, Adjusts Downstream Funding Assumptions; Keeps Outperform Rating MT
RBC Raises Price Target on IGM Biosciences to $9 From $8 on Reduced Ancillary Spend Amid Job Cuts, Keeps Sector Perform, Speculative Risk MT
Medivir to Discuss Birinapant Future Following Partner's Strategic Reprioritization MT
More news
1 day-1.88%
1 week-16.55%
Current month-17.34%
1 month-39.86%
3 months+58.18%
6 months+41.85%
Current year+25.63%
More quotes
1 week
9.62
Extreme 9.62
11.18
1 month
9.62
Extreme 9.62
17.70
Current year
8.14
Extreme 8.135
17.70
1 year
3.81
Extreme 3.81
17.78
3 years
3.81
Extreme 3.81
99.44
5 years
3.81
Extreme 3.81
133.00
10 years
3.81
Extreme 3.81
133.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 03-01-31
Director of Finance/CFO 49 18-12-31
Chief Operating Officer - 20-12-31
Members of the board TitleAgeSince
Director/Board Member 55 21-01-25
Director/Board Member 71 19-01-30
Chief Executive Officer 72 03-01-31
More insiders
Date Price Change Volume
24-03-18 10.44 -1.88% 173,737
24-03-15 10.64 +4.31% 360,526
24-03-14 10.2 +2.51% 317,206
24-03-13 9.95 0.00% 300,336
24-03-12 9.95 -4.78% 383,797

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
IGM Biosciences, Inc. is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The Company has created an IgM antibody technology platform for developing T cell engagers, receptor cross-linking agonists, targeted cytokines and target neutralizers. Its product candidates in clinical testing include IGM-2323 and IGM-8444. IGM-2323 is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in a Phase II clinical trial for the treatment of relapsed/refractory B cell non-Hodgkins lymphoma (NHL) patients. IGM-8444 is an IgM antibody targeting Death Receptor 5 (DR5) proteins for the treatment of patients with solid and hematologic malignancies, is in a Phase I clinical trial for the treatment of solid cancers. Its oncology pipeline also includes IGM-7354, IGM-2644 and IGM-2537.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
10.44 USD
Average target price
21.5 USD
Spread / Average Target
+105.94%
Consensus
  1. Stock
  2. Equities
  3. Stock IGM Biosciences, Inc. - Nasdaq